Sunovion Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

• noting that the Hatch-Waxman framework envisions resolution of the infringement issue earlier, and generally before ANDA approval
• explaining that we first, and primar- ily, rely on intrinsic evidence like the claims themselves when construing claim terms
• noting that the Hatch-Waxman framework envisions resolution of the infringement issue earlier, and generally before ANDA approval
• explaining that even a ' certification to the court to market only product outside the claimed range does not overcome infringement when the ANDA specification is “within thé scope of the issued claims.”
• noting that the intrinsic evidence is “usually dispositive”
• “[I]t is also appropriate to rely on the record of interference proceedings in construing claim terms.”

Source: CourtListener parenthetical corpus (CC0).